Delivery Order SPE2DB22D2206-SPE2DB25FHF16
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $4,195.59 by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Rexulti 2 mg tablets (30-count packages). The contract carries a firm fixed price structure with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 10, 2025, with performance conducted from the vendor's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,077.96 on August 8, 2025, for the supply of Rexulti 1 mg tablets (30-count packages). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 11, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $10,864.83 to AmerisourceBergen Drug Corp for the supply of Rexulti (aripiprazole) 1 mg tablets in a 30-count package. This is a firm fixed-price delivery order with no set-aside designation, awarded on August 20, 2025, and scheduled for completion by August 21, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a $59,725.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units), with an ultimate completion date of June 2, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999.99 million and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $3,043.89 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $31,550.03 to AmerisourceBergen Drug Corp for the supply of Rexulti 0.5 mg tablets (30-count) under contract number 4569070004. This non-competitive delivery order, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $2,033.39 by the Defense Logistics Agency for the supply of Rexulti 2 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's Conshohocken facility. The award represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a $5,123.39 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rexulti 1 mg tablets (30-count units). The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $6.8K delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Rexulti 0.5 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is classified as a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility in...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHF16Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $10,744.78 by the Defense Logistics Agency (DLA) for the supply of Rexulti 4 mg tablets in a 30-count package. This non-competitive, firm fixed-price delivery order was awarded on May 30, 2025, with an ultimate completion date of June 2, 2025. The contract is being performed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026, which authorizes the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical vendor in the federal medical procurement space, AmerisourceBergen Drug Corp regularly fulfills medication orders for military and veteran healthcare systems through its DLA master contract. The supply of Rexulti, a psychiatric medication used in the treatment of schizophrenia and bipolar disorder, represents a typical component of the company's extensive pharmaceutical portfolio delivered to Defense Health Agency and other federal healthcare customers. This delivery order demonstrates the company's role as a primary source for both brand-name and generic pharmaceutical products across multiple therapeutic domains within the Department of Defense supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 5/30/25 |